AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04051255
Drug: full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg
RxNorm normalized name: metronidazole 500 MG
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
Trial: NCT01948648
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
Trial: NCT01948648
Drug: Combination of fish oil and colesevelam
RxNorm normalized name: combinations of levothyroxine and liothyronine
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
Trial: NCT03058965
Drug: [18F]Florbetapir
RxNorm normalized name: [18F]Florbetapir
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
Trial: NCT03058965
Drug: DaTscan
RxNorm normalized name: DaTscan
DrugBank: Ioflupane I-123 (DB08824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
Trial: NCT02219178
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg days 1 - 14 of 21 day schedule
Trial: NCT02219178
Drug: Subcutaneous bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
Trial: NCT02219178
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
Trial: NCT01605890
Drug: emtricitabine / tenofovir disoproxil fumarate / raltegravir .
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.
Trial: NCT02667236
Drug: A-101 Solution
RxNorm normalized name: OXT-101
DrugBank: P-BCMA-101 (DB17371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT00566904
Drug: Epikeia coatings with aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied to affected skin area using a roll-on ball applicator
Trial: NCT00566904
Drug: Epikeia coatings with lidocaine
RxNorm normalized name: Doloracin with Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied to affected skin area using a roll-on ball applicator
Trial: NCT02387099
Drug: 3 weeks Dose Induction of Everolimus
RxNorm normalized name: everolimus 3 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio
Trial: NCT02387099
Drug: 3 weeks Conventional Everolimus Dosing
RxNorm normalized name: everolimus 3 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio
Trial: NCT02387099
Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
RxNorm normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
Trial: NCT03608839
Drug: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
Trial: NCT03608839
Drug: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
Trial: NCT03608839
Drug: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
Trial: NCT00003239
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily by subcutaneous injection.
Trial: NCT00003239
Drug: Omacetaxine Mepesuccinate
RxNorm normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homoharringtonine is administered by continuous infusion on days 1-5.
Trial: NCT01011673
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
Trial: NCT00700596
Drug: Salvinorin A
RxNorm normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
Trial: NCT01632020
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
Trial: NCT01338818
Drug: Ritalin LA (methylphenidate hydrochloride extended release)
RxNorm normalized name: methylphenidate hydrochloride Extended Release Oral Capsule [Ritalin]
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
Trial: NCT02098330
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
Trial: NCT04143685
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cytotec every 4 hours until a maximum of 6 doses
Trial: NCT04143685
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Pitocin through an IVAC until delivery
Trial: NCT00376129
Drug: Alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg i.m. once weekly for 12 weeks
Trial: NCT01962116
Drug: Citrate 4%
RxNorm normalized name: SODIUM CITRATE 4% SOLN
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01962116
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00165880
Drug: E7070
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017602
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02249351
Drug: Talsaclidine
RxNorm normalized name: Talsaclidine
DrugBank: Talsaclidine (DB12287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00233324
Drug: Surfactant
RxNorm normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubation and administration of surfactant by 1 hour of age.
Trial: NCT00057837
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
Trial: NCT00057837
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
Trial: NCT00057837
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
Trial: NCT00057837
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
Trial: NCT03760835
Drug: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
RxNorm normalized name: Cortisone Acetate
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of congenital adrenal hyperplasia
Trial: NCT02053363
Drug: Tranexamic Acid (Cyklokapron)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02385851
Drug: CHS-1701
RxNorm normalized name: CHS-828
DrugBank: CHS-828 (DB12980)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02385851
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01078441
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given subcutaneously.
Trial: NCT01078441
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00139230
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00139230
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00139230
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00139230
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00139230
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02714569
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01887132
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01895218
Drug: Iron isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
Trial: NCT00233324
Drug: Supplemental oxygen with target saturation of 85 to 89%
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
Trial: NCT00233324
Drug: Supplemental oxygen with target saturation of 91 to 95%
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
Trial: NCT03309241
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
Trial: NCT02490241
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
Trial: NCT01252810
Drug: GE-145
RxNorm normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Trial: NCT01548924
Drug: Dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
Trial: NCT01548924
Drug: Dovitinib + Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days.
Trial: NCT01655927
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03427125
Drug: Tenapanor
RxNorm normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT03427125
Drug: Sevelamer Carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active control
Trial: NCT04393246
Drug: EDP1815
RxNorm normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
Trial: NCT04393246
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
Trial: NCT04393246
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
Trial: NCT02858713
Drug: Calcipotriene + Betamethasone Dipropionate
RxNorm normalized name: betamethasone dipropionate / calcipotriene Topical Cream
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
Trial: NCT02033148
Drug: icotinib hydrochloride
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00351754
Drug: Isovue
RxNorm normalized name: Isovue-370
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652795
Drug: Doxycycline Monohydrate
RxNorm normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 150 mg, single-dose
Trial: NCT00652795
Drug: Monodox
RxNorm normalized name: Monodox
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules 50 mg (3 x 50 mg dose), single-dose
Trial: NCT00345761
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
Trial: NCT00345761
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
Trial: NCT01523418
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
Trial: NCT02798835
Drug: Adductor canal block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
Trial: NCT02798835
Drug: Adductor canal block with dexamethasone
RxNorm normalized name: Ivy Block
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
Trial: NCT02798835
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used in spinal anesthetic
Trial: NCT02798835
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
Trial: NCT02798835
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To be given intravenously at time of nerve block to one of the study arms.
Trial: NCT01451489
Drug: FK506
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506:0.05-0.1mg/kg/d
Trial: NCT03630939
Drug: ESR-114
RxNorm normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESR-114 Topical Gel
Trial: NCT00113971
Drug: epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01081145
Drug: Extended-release Guanfacine Hydrochloride
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
Trial: NCT00046995
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03684213
Drug: Control (Norepinephrine)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
Trial: NCT00979251
Drug: Oseltamivir Phosphate
RxNorm normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir Phosphate, q8h
Trial: NCT00979251
Drug: ADS-8902
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h